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Abstract We performed a cross-sectional study that
included 100 HIV-infected Japanese men without hemo-
philia to examine the inﬂuence of smoking on HIV infec-
tion. History of smoking was obtained using a
questionnaire. The percentage of current smokers was
40 % and was the highest (50 %) among men in their
forties. The mean Brinkman index (BI, number of ciga-
rettes smoked per day multiplied by years of smoking) was
450. The percentage of patients with a BI C600 was sig-
niﬁcantly higher in patients with an AIDS-deﬁning event
than in those without an AIDS-deﬁning event. A BI C600
was associated with an AIDS-deﬁning event. Reducing
smoking appears to be critical to enhancing disease man-
agement efforts in Japanese men with HIV.
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Current treatment has signiﬁcantly decreased the mortality
associated with AIDS and prolonged survival of patients
infected with human immunodeﬁciency virus (HIV).
Smoking is a well-known risk factor for conditions such as
cancer, stroke, heart disease, and chronic obstructive pul-
monary disease, and smoking has been independently
associated with morbidity and mortality in HIV-infected
individuals [1–3]. Recent studies have demonstrated that
smoking also is correlated with the stage of HIV [2].
The prevalence of cigarette smoking has been shown to
be particularly high in HIV-infected individuals [1, 3, 4],
ranging from 40 to 70 % in European and North American
HIV cohorts. This smoking rate is two to three times higher
than that in corresponding general populations [3–8].
Smoking characteristics in HIV-infected populations
probably differ from those in the general population
because of factors related to having a chronic life-threat-
ening disease and undergoing treatment for it, related
psychological and behavioral factors, and, in some patients,
other substance abuse issues [9]. Mortality and morbidity
are signiﬁcantly increased in HIV-infected individuals
according to both smoking status and pack-years [10].
However, participants in the studies cited were predomi-
nantly derived from one or two ethnic groups. Cigarette
smoking among HIV-infected individuals in Japan has not
been examined.
This study examines inﬂuence of smoking on HIV
infection among Japanese men with HIV. To our knowl-
edge, this is the ﬁrst study about cigarette smoking among
Japanese HIV-infected patients.
We determined the history of tobacco smoking by using
physician-completed questionnaires with 156 HIV-infected
outpatients without hemophilia who were treated at Junt-
endo University Hospital in Tokyo, Japan between July
2010 and 2011. Patients were eligible if they had evidence
of HIV infection in the form of either positive Western blot
ﬁndings or measurable plasma HIV-1 RNA. A total of 112
HIV-infected patients responded to the questions asked.
Seven patients were excluded because antiretroviral ther-
apy had been initiated at another institution and informa-
tion about their status before treatment was unavailable.
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Two female patients and three non-Japanese patients were
excluded. We selected 100 male respondents based on
retrospective chart review.
This study was approved by the Research Ethics Com-
mittee of Juntendo University School of Medicine, and
informed consent was obtained from each patient.
We obtained patient histories to ascertain demographic
characteristics, HIV risk factors, and previous HIV-related
diagnoses. Patients underwent a baseline physical exami-
nation to examine clinical characteristics. We also used a
questionnaire to obtain history of tobacco smoking. Each
doctor verbally asked about the history of tobacco smoking
by use of a questionnaire and ﬁlled in the answers per-
sonally. All data on smoking in this study were obtained
from the patient responses.
Height and weight were measured following a standard
procedure and body mass index (BMI) was calculated as
weight/height (kg/m2). Venous blood was drawn from the
patients. The most recent laboratory data were obtained
from patients who had never received antiretroviral therapy,
and just before initiating antiretroviral therapy from those
who had, to exclude inﬂuences of antiretroviral therapy.
Descriptive statistics are reported as means with stan-
dard SD or medians. Smoking status was expressed in the
terms of the Brinkman index (BI, number of cigarettes
smoked per day multiplied by years of smoking) [11].
Patients with and without an acquired immunodeﬁciency
syndrome (AIDS)-deﬁning event were compared. Demo-
graphic and clinical characteristics were compared between
these two groups using the unpaired t test, Mann–Whitney
U test, or chi-square test. The level of statistical signiﬁ-
cance was deﬁned as P\ 0.05, and all data were analyzed
using JMP version 9 (SAS Institute).
A total of 100 Japanese men were included in this
analysis. Mean age was 42 ± 13 years, and 29 % (26/90)
had an AIDS-deﬁning event. Mean baseline CD4 lym-
phocyte count was 221 ± 25.1/ll and mean baseline log10
HIV-1 RNA was 4.5 ± 0.7 copies/ml (Table 1). Forty
percent (40/100) were current smokers, and mean BI was
450 ± 53. Among our patients, 74 % (59/80) were men
who have sex with men (MSM), and 1 % (1/100) had a
history of intravenous drug use. A total of 78 % (71/91) of
patients received antiretroviral therapy based on guidelines
for the use of antiretroviral agents in HIV-1-infected adults
and adolescents [12] (Table 1).
The percentage of current smokers was 40 % and was
the highest (50 %) among men in their forties (Fig. 1). The
percentage of current smokers in our study was 23.1 % in
their twenties, 48.6 % in their thirties, 50 % in their forties,
26.7 % in their ﬁfties, and 20 % in their sixties (Fig. 1);
that of the general Japanese male population in 2011 was
35.2 % in their twenties, 40.6 % in their thirties, 39.2 % in
their forties, 40.9 % in their ﬁfties, and 23.9 % in their
sixties [13]. The peak percentage of current smokers was in
a younger generation than that in the general Japanese male
population. This ﬁnding was consistent with previous
reports based on other ethnic populations [3–8].
The percentage of patients with a BI C600 was signif-
icantly higher in patients with AIDS-deﬁning events than
those without AIDS-deﬁning events (Table 2). Wojna et al.
[2] reported that current smoking was correlated with
higher HIV RNA level and history of smoking was corre-
lated with lower CD4 lymphocyte counts. Feldman et al.
[14] showed that smokers initially had higher CD4 lym-
phocyte counts and AIDS-deﬁning events than those who
had never smoked.
The cross-sectional study design and small sample size
of our study limited our ability to assess causal associations
Table 1 Patient characteristics
Factors N Mean ± SD Factors n Number
(weighted
%)
Age (years) 100 42.1 ± 12.7 HIV
treatment
history
(yes)
91 71 (78.0)
BMI (kg/m2) 82 21.9 ± 3.4 AIDS-
deﬁning
event
(yes)
90 26 (28.9)
Brinkman
index
64 450 ± 53 MSM (yes) 80 59 (73.8)
HIV RNA
level (log
copies/ml)
88 4.5 ± 0.70 Drug (yes) 100 1 (1.0)
CD4 (cells/nl) 89 221 ± 25.1 Smoker
(current/
previous)
64 40/24
(40.0/
24.0)
Value are mean ± SD and number (weighted %)
BMI body mass index, MSM men who have sex with men
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Fig. 1 Percentage of current smokers classiﬁed by age
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of smoking with HIV infection. In addition, the tax rate of
cigarettes increased in Japan in October 2010 [15], which
may have inﬂuenced the percentage of current smokers in
our study.
In conclusion, the peak percentage of current smokers
was in the younger generation and was higher among HIV-
infected patients selected from Japanese men compared to
the general Japanese male population. A BI C600 was
associated with AIDS-deﬁning events in HIV-infected
Japanese men. Therefore, smoking cessation is critical to
enhancing disease management efforts in HIV-infected
patients.
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Table 2 Comparison of patients with and without an AIDS-deﬁning
event
Baseline
characteristics
n With AIDS-
deﬁning event
(n = 17)
Without AIDS-
deﬁning event
(n = 41)
P value
Age (years) 58 47.6 ± 3.08 42.3 ± 1.98 0.1553a
BMI (kg/m2) 52 22.0 ± 1.36 21.6 ± 0.40 0.1743b
MSM 40 11 (73.3 %) 29 (82.9 %) 0.4404c
CD4 (cells/ll) 57 37.3 ± 11.2 275 1 30.9 \0.0001b, *
HIV RNA
level (log
copies/ml)
56 4.82 ± 0.13 4.43 ± 0.11 0.0638b
Brinkman
index
64 578 ± 121 357 ± 39.5 0.1179b
Brinkman
index C600
11 6 (35.3%) 5 (12.2 %) 0.0411c, *
Value are mean ± SD and number (weighted %)
BMI body mass index, MSM men who have sex with men
* P\ 0.05
a Unpaired t test
b Mann–Whitney U test
c Chi-square test
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